Market revenue in 2023 | USD 27,253.8 million |
Market revenue in 2030 | USD 49,374.1 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Personalized nutrition & wellness |
Fastest growing segment | PM Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Illumina Inc, Asure Software Inc, Abbott Laboratories, Danaos Corp, Exact Sciences Corp, Danaher Corp, Amgen Inc, Qiagen NV, Exagen Inc Ordinary Shares, Quest Diagnostics Inc, Biogen Inc, Genelux Corp, International Business Machines Corp, Genentech, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to personalized medicine market will help companies and investors design strategic landscapes.
Personalized nutrition & wellness was the largest segment with a revenue share of 32.98% in 2023. Horizon Databook has segmented the Japan personalized medicine market based on pm diagnostics, pm therapeutics, personalized medical care, personalized nutrition & wellness covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s personalized medicine market accounted for a significant revenue share in 2020. This share is due to the outcome of an active expansion strategy under execution by several market participants to strengthen their position in the Asia Pacific region.
Japan is the first country to approve Rozlytrek—a precision medicine offered by Roche. In June 2019, the Ministry of Health, Labour and Welfare of Japan approved Rozlytrek indicated for the management of neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors in patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan personalized medicine market , including forecasts for subscribers. This country databook contains high-level insights into Japan personalized medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account